Drugs / Depigoid
Depigoid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01734265 | Nov 2012 → Mar 2013 | allergic disease, asthma, rhinitis | Laboratorios Leti, S.L. | Completed | No outcome recorded |
| Phase 2 | NCT01591343 | Jun → Jul 2012 | allergic rhinitis, intermittent asthma | Laboratorios Leti, S.L. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00396409 | Feb 2006 → Aug 2008 | allergic asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00622362 Comparator | Jan 2008 → Feb 2009 | allergic asthma | Laboratorios Leti, S.L. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Depigoid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00396409 ↗ |
| Known as | Depigoid 50% D. pteronyssinus / 50% D. farinae | “Test product, dose and mode of administration: Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).” NCT01591343 ↗ |
| Known as | Depigoid D. pteronyssinus | “Test product, dose and mode of administration: Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).” NCT01591343 ↗ |
| Modality | Other / unclassified | “specific immunotherapy (Depigoid)” NCT00396409 ↗ |
| Route | Subcutaneous | “Subcutaneous administration” NCT00622362 ↗ |